Home Infusion for Lupus: Benlysta and Biologic Therapy Options for SLE

June 25, 2026

Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the immune system generates antibodies that attack the body's own tissues, affecting the joints, skin, kidneys, heart, lungs, and nervous system. For patients with moderate-to-severe lupus that is inadequately controlled by conventional medications, IV biologic therapies offer a targeted approach to disease management.


For many lupus patients on stable biologic therapy, receiving these infusions through home infusion therapy is a clinically appropriate alternative to repeated infusion center visits. Pharmko coordinates lupus biologic infusions for patients and rheumatologists across 22+ states.


IV Biologic Therapies Used in Lupus


Benlysta (belimumab)


Benlysta is a monoclonal antibody that targets BLyS (B lymphocyte stimulator), a protein that supports the survival of autoreactive B cells, cells that produce the antibodies driving lupus inflammation and organ damage. By blocking BLyS, Benlysta reduces the number and activity of these harmful B cells, lowering disease activity and reducing flare frequency.

Benlysta is FDA-approved for active, autoantibody-positive SLE in adults and for active lupus nephritis. It is available in two formulations: IV infusion (given monthly after loading doses at weeks 0, 2, and 4) and subcutaneous injection (given weekly). The IV formulation is administered over one hour and is the standard route for patients initiating therapy or who prefer monthly dosing over weekly self-injection.


Saphnelo (anifrolumab)


Saphnelo is a newer IV biologic approved in 2021 for moderate-to-severe SLE in adults on standard therapy. It blocks the type I interferon receptor, a signaling pathway overactivated in many lupus patients and associated with disease flares and organ damage. Saphnelo is administered by IV infusion every 4 weeks over 30 minutes.


Because Saphnelo is relatively new, fewer patients have transitioned to home infusion compared to Benlysta, but it is appropriate for home administration in stable patients following the same criteria as other IV biologics.


IVIG in Lupus


Intravenous immunoglobulin (IVIG) is used off-label in certain severe manifestations of lupus, including thrombocytopenia, hemolytic anemia, and neuropsychiatric lupus, typically as a bridge therapy or when conventional immunosuppressants are contraindicated. It is not a first-line treatment for SLE but plays a role in acute flare management.


Who Qualifies for Home Infusion of Lupus Biologics?


Home infusion of IV lupus biologics is appropriate for patients who:


  • Have received their initial loading doses (weeks 0, 2, and 4 for Benlysta) in a supervised clinical setting without significant infusion reactions
  • Are on a stable, maintenance dosing schedule
  • Have been assessed by their rheumatologist as clinically stable for home-based administration
  • Have lupus nephritis or other organ involvement that is being actively monitored but does not require inpatient care


Patients with active lupus flares, new organ involvement, or recent serious infections typically require physician-supervised infusions until their clinical situation is stabilized.


What to Expect During a Home Lupus Infusion


Before the infusion


A Pharmko nurse reviews your current medications, confirms the absence of active infection, checks vital signs, and prepares the medication. Pre-medications may be administered per your rheumatologist's orders.


During the infusion


Benlysta infusions run over one hour; Saphnelo over 30 minutes. Your nurse monitors your vital signs throughout and is present to respond to any reaction. The infusion rate may be slowed if you experience nausea, headache, or other mild symptoms.


After the infusion


Your nurse documents the session and communicates with your rheumatologist's office. Know which symptoms require an immediate call in the hours following your infusion, including fever, chest tightness, or new joint swelling, and save our after-hours support number before your first home dose.

Lupus and the Broader Autoimmune Infusion Landscape


Lupus patients may also have overlapping conditions, particularly Sjögren's syndrome, antiphospholipid syndrome, or lupus nephritis, that introduce additional treatment considerations. For patients managing multiple autoimmune conditions treated with IV biologics, our guide on home infusion for autoimmune diseases provides a broader overview of how these therapies are coordinated. For Crohn's disease specifically, which shares some biologic treatment pathways, see our guide on home infusion for Crohn's disease.


Insurance Coverage for Lupus Biologic Infusions


Benlysta and Saphnelo are covered under the medical benefit by Medicare Part B and most commercial insurance plans when administered by a licensed provider to patients with documented active, autoantibody-positive SLE. Prior authorization is required and must include lab documentation of autoantibody positivity and evidence of inadequate response to standard therapy. Pharmko manages the full authorization process and communicates any coverage issues before your first home infusion.


Contact Pharmko to start a lupus infusion referral: 1-877-540-2003


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More